This program project is concerned with the study of the biology and regulation of the hypothalamo-pituitary-adrenal (HPA) axis, with particular emphasis on peptide biology. The peptides of interest are the hypothalamic neuropeptides, arginine vasopressin (AVP), pro-dynorphin and corticotropin releasing factor (CRF), and the anteror pituitary peptide family, pro- opiomelanocortin (POMC). The four projects involved in this program range from basic animal studies of the dynorphin- vasopressin systems, to clinical human studies of the HPA dysregulation in major depression. Nevertheless, these projects are closely interrelated in terms of attempting to derive a basic understanding of the regulation and dynamics of the HPA axis. This is predicated on the notion that such as improved knowledge base will be useful in elucidating the function of the peptides in this stress-related system, and the responsiveness of the various elements to changing demands, either under normal or psychopathological conditions. Specifically, Project 1 focuses on the opioid peptide family pro- dynorphin, which is co-stored with AVP in hypothalamic magnocellular neurons. Since AVP is a known ACTH/B- Endorphin secretagogue, a potential role of dynorphin in this stress-related function will be explored. In addition the posterior lobe and the anterior lobe dynorphin systems will serve as valuable models for studying its biosynthesis and regulation. Project 2 is a preclinical proposal looking at the effect of variables such as age, sex and tricyclic treatment on the cellular regulation of POMC in the anterior lobe. Project 3 is a clinical project exploring the HPA axis in major depression with basal measures and challenge studies using corticosteroids and CRF. Project 4 is a collaborative inter-university effort focused on CRF challenges in depression. The multidisciplinary approach involves the use of molecular biology immunohistochemistry, peptide measurements and characterization, biosynthesis and release studies and behavioral and pharmacological challenges. Information derived from each of the projects will be considered in the interpretation of results from the other projects. The net result should be increased insight in the biology of stress and depression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH042251-02
Application #
3099066
Study Section
(SRCM)
Project Start
1986-12-01
Project End
1991-11-30
Budget Start
1987-12-01
Budget End
1988-11-30
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Meyers, K K; Crane, N A; O'Day, R et al. (2015) Smoking history, and not depression, is related to deficits in detection of happy and sad faces. Addict Behav 41:210-7
Lohoff, F W; Hodge, R; Narasimhan, S et al. (2014) Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry 19:129-39
Tomita, Hiroaki; Ziegler, Mary E; Kim, Helen B et al. (2013) G protein-linked signaling pathways in bipolar and major depressive disorders. Front Genet 4:297
Votruba, Kristen L; Langenecker, Scott A (2013) Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test. J Clin Exp Neuropsychol 35:132-46
Turner, Cortney A; Watson, Stanley J; Akil, Huda (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160-74
Vederman, Aaron C; Weisenbach, Sara L; Rapport, Lisa J et al. (2012) Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex 48:1027-34
Turner, Cortney A; Clinton, Sarah M; Thompson, Robert C et al. (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci U S A 108:8021-5
Mickey, Brian J; Zhou, Zhifeng; Heitzeg, Mary M et al. (2011) Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68:158-66

Showing the most recent 10 out of 75 publications